Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics
Exposure therapy has been a common treatment for anxiety disorders (especially OCD) since the 70’s. It involves gradually exposing patients to triggering situations in a safe environment so they can work through their irrational response.
Now imagine being exposed to your triggers through immersive virtual reality… while on psychedelics.
It may sound scary, but psychedelics could actually provide feelings of safety and allow patients to change their perspective and response to the stimuli.
This is how Incannex Healthcare (IXL) plans to treat patients with severe anxiety disorders in upcoming trials in collaboration with Monash University.
The Australian company debuted on the Nasdaq this week under the symbol ‘IXHL’.